ConductScience.org, home

Paper39875346

Seventy Years Later: Systemic and Local Properdin in Atherosclerosis.

Regal JF and 1 other. J Am Heart Assoc, 2025. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Seventy Years Later: Systemic and Local Properdin in Atherosclerosis. Papers, record 39875346. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39875346

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Seventy Years Later: Systemic and Local Properdin in Atherosclerosis.
PubMed
Journal
J Am Heart Assoc
PubMed
Year
2025
PubMed
Publication types
Editorial, Comment
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-05-15
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Regal JFJean Fhttps://orcid.org/0000-0001-5713-0891
2Fleming SDSherry Dhttps://orcid.org/0000-0001-5385-7233

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment on39,868,499Alternative Complement Pathway in Carotid Atherosclerosis: Low Plasma Properdin Levels Associate With Long-Term Cardiovascular Mortality.https://conductscience.org/library/papers/39868499

Source PubMed

References18

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137,662,914Properdin inhibition ameliorates hepatic ischemia/reperfusion injury without interfering with liver regeneration in mice.Front Immunol2023https://conductscience.org/library/papers/37662914PubMed
237,499,656Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis.Immunity2023https://conductscience.org/library/papers/37499656PubMed
34,134,064Activation of the alternate pathway of human complements by rabbit cells.J Immunol1974https://conductscience.org/library/papers/4134064PubMed
433,868,287Complement Initiation Varies by Sex in Intestinal Ischemia Reperfusion Injury.Front Immunol2021https://conductscience.org/library/papers/33868287PubMed
526,091,721The role of complement activation in atherogenesis: the first 40 years.Immunol Res2016https://conductscience.org/library/papers/26091721PubMed
639,868,499Alternative Complement Pathway in Carotid Atherosclerosis: Low Plasma Properdin Levels Associate With Long-Term Cardiovascular Mortality.J Am Heart Assoc2025https://conductscience.org/library/papers/39868499PubMed
731,263,464Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.Front Immunol2019https://conductscience.org/library/papers/31263464PubMed
838,600,367Canonical and non-canonical roles of complement in atherosclerosis.Nat Rev Cardiol2024https://conductscience.org/library/papers/38600367PubMed
97,010,302A war with the molecules: Louis Pillemer and the history of properdin.Perspect Biol Med1980https://conductscience.org/library/papers/7010302PubMed
1028,139,294C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.Kidney Int2017https://conductscience.org/library/papers/28139294PubMed
114,176,223Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components.J Exp Med1968https://conductscience.org/library/papers/4176223PubMed
1229,954,621Properdin: A multifaceted molecule involved in inflammation and diseases.Mol Immunol2018https://conductscience.org/library/papers/29954621PubMed
1323,184,055Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency.J Am Soc Nephrol2013https://conductscience.org/library/papers/23184055PubMed
156,993,558Presidential address to American Association of Immunologists in Anaheim, California, April 16, 1980. Louis Pillemer, Properdin, and scientific controversy.J Immunol1980https://conductscience.org/library/papers/6993558PubMed
1635,365,353The multifaceted impact of complement on atherosclerosis.Atherosclerosis2022https://conductscience.org/library/papers/35365353PubMed
1736,713,423A novel assay that characterizes properdin function shows neutrophil-derived properdin has a distinct oligomeric distribution.Front Immunol2022https://conductscience.org/library/papers/36713423PubMed
1924,667,818Protective role for properdin in progression of experimental murine atherosclerosis.PLoS One2014https://conductscience.org/library/papers/24667818PubMed
2031,849,925Properdin: A Novel Target for Neuroprotection in Neonatal Hypoxic-Ischemic Brain Injury.Front Immunol2019https://conductscience.org/library/papers/31849925PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39875346

GET https://conductscience.org/api/papers/v1/39875346/authors